Indeed, LRP6 can inhibit the development of atherosclerosis by regulating several signaling pathways, including the Wnt5a/Rac1, Wnt/β-catenin, Wnt/PCP, Sp1-dependent PDGF, glycogen synthase kinase 3 beta (GSK-3β)/insulin receptor substrate 1 (IRS1), insulin-like growth factor 1 (IGF1)/mechanistic target of rapamycin kinase (mTOR)/sterol response element binding protein 1/2 (SREBP1/2), and dynamin-related protein 1 (DRP1)/mTOR/transcription factor EB (TFEB) signaling pathways (Alrefaei and Abu-Elmagd, 2022; Kang, 2020). The gene discussed is TFEB; the disease is atherosclerosis.